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Background: A cochlear implant (CI) is an artificial hearing device that can replace a damaged cochlea. The present
study examined the use of growth factor-eluting gelatin hydrogel coatings on the electrodes to minimize inner ear
trauma during electrode insertion. Insulin-like growth factor 1 (IGF1) and/or hepatocyte growth factor (HGF) were chosen
as the agents to be administered.
Methods: Silicone CI electrode analogs were prepared and coated with gelatin hydrogels. Adsorption/release profile of
the hydrogel was measured using 125I-radiolabeled IGF. Hydrogel-coated electrodes were absorbed with IGF1, HGF,
IGF1 plus HGF, or saline (control) and implanted into the basal turns of guinea pig cochleae (n = 5). Auditory sensitivity
was determined pre-operatively, immediately after, and 3, 7, 14, 21, and 28 days post-operatively by using auditory
brainstem response (ABR; 4–16 kHz). In addition, histological analysis was performed and auditory hair cell (HC) survival,
spiral ganglion neuron (SGN) densities, and fibrous tissue thickness were measured.
Results: Compared to non-coated arrays, hydrogel-coated electrodes adsorbed significantly greater amounts of
IGF1 and continuously released it for 48 h. Residual hearing measured by ABR thresholds after surgery were elevated
by 50–70 dB in all of the electrode-implanted animals, and was maximal immediately after operation. Thresholds were
less elevated after hydrogel treatment, and the hearing protection improved when IGF1 or HGF was applied.
Histopathologically, hair cell survival, spiral ganglion cell survival, and fibrous tissue thickness were not different
between the experimental groups. No serious adverse events were observed during the 4-week observation
period.
Conclusions: Our findings provide the first evidence that hydrogel-coated, growth factor-releasing CI electrodes
could attenuate insertional trauma and promote recovery from it, suggesting that this combination might be a
new drug delivery strategy not only in cochlear implantation but also in treating clinical conditions characterized
by inner ear damage.
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Cochlear implants (CIs) provide auditory perception to in-
dividuals with severe to profound sensorineural hearing
loss by electrically stimulating spiral ganglion neurons
(SGNs) via an electrode array implanted into the cochlea
[1]. Recent advances in CI technology have led to the de-
velopment of a new generation of hearing-preserving CIs
with less traumatic electrodes that minimize inner ear
trauma during electrode insertion. This is particularly true
for those with some residual hearing who may benefit
from newly emerging stimulus strategies that employ a
combination of electrical and acoustic stimulation. More-
over, insertional trauma can also lead to scar [2] and fi-
brous tissue formation that could result in impedance
increase and residual hearing decrease [3,4].
Two surgical strategies have been used to reduce inser-
tional trauma: soft surgery and targeted drug delivery.
However, even with the introduction of minimally trau-
matic “soft” surgical techniques (reviewed in [5] and [6])
and electrodes that have been modified to reduce intraco-
chlear trauma during their insertion [7], residual hearing
is lost or incompletely preserved in one-third of cases [8].
Some researchers have begun to explore the possibility
that better hearing preservation may be achieved by the
application of protective pharmacological agents to the
inner ear at the time of surgery ([9,10] and [11], reviewed
in [6]).
Advanced drug delivery systems (DDS) present in-
dubitable benefits for drug administration. Over the
past three decades, new approaches have been sug-
gested for the development of novel carriers for drug
delivery. Gelatin is a protein obtained by the partial hy-
drolysis of collagen. This biodegradable, biocompatible,
and non-immunogenic compound is commonly used in
the biomedical field (e.g., drug delivery vehicles and
wound dressings). Gelatin hydrogels can be electrostati-
cally combined with other proteins [12] to form a bio-
degradable carrier. Incorporated proteins are continuously
released by the enzymatic degradation of the gelatin poly-
mers after application.
We have developed insulin-like growth factor 1 (IGF1)-
and hepatocyte growth factor (HGF)-containing hydrogels
[13] and conducted a series of animal experiments, which
revealed that topical growth factor application via gelatin
hydrogels significantly improved hearing by protecting
auditory hair cells (HCs) against damage caused by intense
noise exposure [14,15], drug-induced hearing loss [16], or
ischemic injury [17], with no adverse events. IGF1 inhibits
apoptosis and promotes cell cycle progression to maintain
HC numbers in the injured cochlea [18]. Furthermore,
our human clinical trial showed the effectiveness of IGF1
hydrogel treatment in patients with idiopathic sudden sen-
sorineural hearing loss that is refractory to glucocorticoid
treatment [19].In the present study, we examined whether growth
factor-eluting hydrogels could be used to reduce the
trauma associated with cochlear implantation. CI elec-
trode analogs were coated with IGF1- or HGF-containing
gelatin hydrogels and their release profile was measured.
Hydrogel electrodes were then implanted in guinea pig




The biodegradable hydrogels were prepared as described
previously [15,20]. A previous analysis of in vitro HGF-
release profiles from hydrogels has demonstrated that a
hydrogel, isoelectric point (IEP) 5.0, made with 5 wt%
glutaraldehyde allows optimal HGF delivery [21]. We
therefore used this type of hydrogel in the present study.
Preparation of electrode samples
Silicone guinea pig CI electrode analogs, 0.38 mm in
diameter, were prepared specially for this experiment. Syl-
gard 184 silicone elastomer (Dow Corning, USA) solution
was mixed and degassed and filled in PE20 polyethylene
tubing (Clay Adams, USA) and cured at 60°C for 12 h.
Electrode samples were then coated with gelatin hydro-
gels. Electrode’s silicone surface was treated with corona
plasma discharge (100 V, 60 sec) and thereafter gelatin
hydrogel (IEP 4.77) was cross-linked with 5 wt% acidic
gelatin aqueous solution [13]. In the adsorption of IGF1
experiment, selected electrodes were coated twice to en-
sure thick coating.
Adsorption/release of IGF1 from hydrogel-coated
electrodes
Preparation of 125I-radiolabeled IGF was performed ac-
cording to the method reported previously [13]. Briefly,
recombinant human insulin-like growth factor-1 (rhIGF1,
Sigma-Aldrich, USA) was radiolabeled with Iodine 125
(125I)-labeled sodium iodide (PerkinElmer, USA) with
chloramine T and sodium metabisulfite. Then, a hydrogel-
coated electrode (1-cm long) was immersed with 5 μL of
125I-labeled rhIGF1 and 1 mL of phosphate buffered saline
(PBS) in a test tube for 1 h at 37°C. After 1 h, PBS was
completely removed and radioactivity in the supernatant
was determined with a scintillation counter (Beckman,
USA) to calculate adsorbed IGF1.
To measure in vitro release of IGF1, fresh PBS, with or
without type I collagenase (Gibco-Invitrogen, USA), was
added to the rhIGF1-conjugated hydrogel electrodes. The
tubes were gently agitated at 37°C and the buffer was
changed periodically at 0.5, 1, 2, 4, 8, 24, and 48 h. The
radioactivity of the buffer was measured with a scintilla-
tion counter.
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Four to 9-week-old adult male Hartley guinea pigs (weight,
300–450 g; Japan SLC, Hamamatsu, Japan) served as ex-
perimental animals. The Animal Research Committee of
the Graduate School of Medicine at Kyoto University ap-
proved all experimental protocols (MedKyo14169). Animal
care was conducted under the supervision of the Institute
of Laboratory Animals at the Graduate School of Medicine,
Kyoto University. All experimental procedures were per-
formed in accordance with the National Institutes of
Health guidelines for the care and use of laboratory ani-
mals. All efforts were made to limit the number of animals
used and their suffering.
Surgical procedure and drug application
Hydrogel-coated electrodes (3.3-mm long) were immersed
for 12 h in 10 μL physiologic saline solution with
rhIGF1 or recombinant human HGF (rhHGF, Sigma-
Aldrich, USA) or mixture of rhIGF1 and rhHGF at a con-
centration of 0.05 mg/mL or 0.5 mg/mL, respectively. As
controls, non-coated electrodes or hydrogel only elec-
trodes (immersed in physiologic saline) were used.
All surgeries were performed by the same surgeon
(Y.S.K.) under general anesthesia, that is, intra-muscular
injection of midazolam (2 mg/kg) and xylazine (2 mg/kg).
After opening the tympanic bulla of the temporal bone, a
cochleostomy was performed on the basal turn of the
cochlea and the dummy electrode was carefully inserted
from the hole. After insertion, the stoma was tightly sealed
with bone wax, soft tissue, and fibrin glue.
Functional analysis
Auditory function was assessed by measuring hearing
thresholds of each ear, i.e., auditory-evoked brainstem re-
sponses (ABRs) in response to pure-tone stimuli. ABR
measurements were performed at frequencies of 4, 8, and
16 kHz before and after surgery, and on days 3, 7, 14, 21,
and 28 after electrode insertion. Bioelectrical potentials
were recorded using subdermal stainless steel needle elec-
trodes inserted at the vertex (ground), ventrolateral to the
measured ear (active) and contralateral to the measured
ear (reference). Thresholds were determined from a set of
responses at varying intensities with 5-dB SPL intervals
and electrical signals were averaged for 1024 repetitions.
Thresholds at each frequency were verified at least twice.
Histological analysis
On day 28 after electrode insertion, animals were deeply
anesthetized with midazolam and xylazine, euthanized
with pentobarbitone sodium, and transcardially perfused
with phosphate-buffered 0.9% saline solution followed by
phosphate-buffered 4% paraformaldehyde solution. Tem-
poral bones were harvested and fixed with 4% paraformal-
dehyde in 0.01 mol/l PBS, decalcified with 4% EDTA,cryoprotected with 30% sucrose solution, and embed-
ded in OCT compound (Tissue-Tek, USA). Cryosec-
tions (10-μm thickness) were made and stained with
hematoxylin and eosin (HE) or Mallory’s trichrome kit
(Sigma-Aldrich).
Hair cell survival
Auditory HC survival rate was measured as described
previously [22]. The number of remaining HCs at the
basal, second, and third turn was counted at least in 6
sections per animal. HCs were counted as present if the
cell body and cuticular plate looked intact. We calcu-
lated the inner and outer hair cell (IHC and OHC) sur-
vival rates of these three turns in each animal by using
the following formulae: IHC survival rate% = 100 × [(the
number of present IHCs of examined specimens)/(the
number of examined specimens)]; OHC survival rate% =
100 × [(the number of present OHCs of examined speci-
mens)/(the number of examined specimens)/3].
Spiral ganglion neuron count
SGN counting in Rosenthal’s canals was performed in ac-
cordance with a method that has previously been described
[23]. An unbiased investigator inspected the collection of
mid-modiolar sections generated for each cochlea and
determined SGN numbers in the each turn of the coch-
leae from 6 randomly selected sections that underwent
surgery. The cross-sectional areas of Rosenthal’s canals
were measured using Image/J software (http://imagej.
nih.gov/ij/). SGN densities were then calculated by div-
iding the number of SGNs by the area. This value was
used to reduce the variance caused by differences in the
cutting directions among the cochlear specimens.
Fibrous tissue thickness
The collagen deposition for each trichrome-stained spe-
cimen was determined in at least 6 slides per cochlea,
and fibrous tissue thickness was determined by measur-
ing the maximum perpendicular length of fibrous cap-
sule surrounding the implanted electrode.
Statistical analysis
Adsorption of rhIGF1 into hydrogel-coated or non-coated
electrodes was analyzed with one-way analysis of variance
(ANOVA) using the Statcel2 application (OMS Publish-
ing, Saitama, Japan). Values of p less than 0.05 were con-
sidered statistically significant. For interactions that were
found to be significant, multiple paired comparisons were
further analyzed using the Tukey–Kramer test.
The overall effects of the hydrogel-growth factor appli-
cation on in vivo ABR thresholds were examined with
repeated-measures ANOVA. P values < 0.05 were con-
sidered statistically significant.
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ganglion cell survival, and fibrous tissue thickness) were
analyzed with one-way ANOVA.Results
Adsorption and release profile of IGF1 from
hydrogel-coated electrodes
First, we evaluated the adsorption of IGF1 to the syn-
thesized electrodes by radioactivity assay, i.e., measur-
ing relative intensities of radioactivity on the electrodes
after they were immersed in 125I-labeled IGF1 solution
for 1 h. Figure 1A shows adsorption of non-coated bare
electrodes and hydrogel-coated samples. Single-hydrogel-
coated (gel (+)) electrodes adsorbed 37.6 ± 2.3% (mean ±
SD) of given IGF1 in the solution, whereas double-coated
(gel (++)) and non-coated (gel (−)) arrays absorbed 39.8 ±
4.2% and 23.4 ± 6.7%, respectively. Both single- and
double-coated electrodes showed significant adsorption
of IGF1 over bare electrode (P < 0.01). There was no
statistical difference between single- and double-coated
arrays.
Release profiles of the IGF1 electrodes are shown in
Figure 1B. Since human body fluids contain certain
amount of collagenase and have gelatinolytic activity, we
tested the release of IGF1 from electrodes in collagenase-
containing saline. Test samples gave a biphasic release
profile with an initial burst release (1 h) followed by
secondary slow release phase over the 48-h study
period. In collagenase-containing environment, thick-
coated electrodes released more drug than other coated or
non-coated electrodes (black boxes). Of all three types,
single-coated electrodes retained most IGF1 in collagenase
fluids, e.g., 7.3 ± 1.1% (mean ± SD) after 24 h (gray boxes).A B
Figure 1 Adsorption and release profiles of gelatin hydrogel-coated C
of rhIGF1 was expressed by relative radioactivities of incorporated 125I-labe
single-hydrogel-coated and double-coated electrodes, respectively. Error ba
the rhIGF1 radioactivity on test electrodes after gently agitated in 37°C pho
that even after 24 h, hydrogel-coated electrodes retained more than 7% ofAlterations in ABR thresholds after drug-eluting electrode
insertion
To evaluate surgical damage-reducing effect of these
electrodes, changes in auditory function of operated ani-
mals were measured. ABR thresholds at 4, 8, and 16 kHz
were recorded before, immediately after surgery, and 3,
7, 14, 21, and 28 days post-operatively (Figure 2). Pre-
treatment baseline ABR thresholds did not differ among
the five groups and were consistent with data previously
obtained in our laboratory [15]. Our surgical procedure
caused average hearing loss around 61 dB, whereas non-
coated, hydrogel-coated, IGF1, HGF, and IGF plus HGF
electrodes shifted ABR thresholds by 70 ± 14, 57 ± 11,
52 ± 20, 62 ± 21, and 65 ± 26 dB (mean ± SD), respect-
ively. ABR thresholds recovered consistently in IGF1 or
HGF electrode groups during the 4-week test period,
leading to significant differences over bare electrode at
each ABR frequency and their average (P < 0.05). In con-
trast, IGF plus HGF electrode showed significant differ-
ence only at high frequency (16 kHz). Hydrogel-coated
electrode without medication showed significant effect
after 4 weeks at average ABR; further analyses revealed
hydrogel-only group showed reduced hearing loss up
until 2 weeks at low frequency (4 kHz, P < 0.025).
Survival of the HCs
All guinea pigs displayed loss of outer hair cells
(OHC) in all turns, more significantly in the basal
turn, whereas IHCs displayed no or only a little loss
(Figures 3 and 4A). The total IHC survival rates (mean ±
SD) in non-coated, hydrogel-coated, IGF1, HGF, and IGF
plus HGF electrodes-inserted guinea pigs were 95.1% ±
7.0%, 98.3% ± 5.8%, 86.1% ± 15.5%, 84.6% ± 26.7%, and
90.0% ± 10.9%, respectively. Although not statisticallyI electrodes for recombinant human IGF1 (rhIGF1). (A) Adsorption
led rhIGF1 (n = 6). Gel (−), gel (+) and gel (++) represent non-coated,
rs indicate the standard deviation (SD). *P < 0.01. (B) Time-course of
sphate-buffered saline (PBS), with or without type I collagenase. Note
IGF1 in natural environment (gray boxes).
Figure 2 Alterations in ABR thresholds after drug-eluting electrode insertion. ABR thresholds at 4, 8 and 16 kHz were obtained before,
immediately after surgery and repeated for 4 weeks until the end of the treatment (n = 5 per group). Graphs show ABR thresholds in decibels
(mean ± SD) of average of three frequencies (4, 8, and 16 kHz). Repeated measures ANOVA of average ABR thresholds revealed significant
differences between non-coated (gel (−)) and IGF1- (gel (+) IGF1) or HGF-adsorbed (gel (+) HGF) hydrogel electrodes (*P < 0.05). Hydrogel-coated
electrode without medication (gel (+)) showed superior protective effect over bare electrode. In individual frequency analyses at 4, 8, or 16 kHz,
IGF1 or HGF electrode showed significant attenuation of hearing loss after surgery, whereas IGF plus HGF electrode showed significant differences
only at 16 kHz. Gel (+) electrode showed significant hearing loss-reducing effect until 2 weeks after surgery in analyses using 4 kHz ABR
thresholds (**P < 0.025).
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ond and third turns in hydrogel-coated guinea pigs
when compared to non-coated counterparts.
In contrast, greater variance was observed in the ex-
tent of OHC loss. The total OHC survival rates in
non-coated, hydrogel-coated, IGF1, HGF, and IGF plus
HGF electrodes-inserted guinea pigs were 77.5% ±
11.6%, 65.6% ± 16.1%, 71.2% ± 17.9%, 76.3% ± 13.9%,
and 78.1% ± 12.8%, respectively. In hydrogel-coated elec-
trode GPs, the OHC survival rates in the basal turns were
relatively lower when compared to those of non-coated or
growth factor-treated ones (not statistically significant). In
contrast, there was no significant difference in all GPs at
either second or third turns of the cochlea.
Spiral ganglion cell (SGC) density
We quantified the histological damage to SGNs by meas-
uring SGC densities in Rosenthal’s canals (Figure 4B). Thetotal SGC densities in non-coated, hydrogel-coated, IGF1,
HGF, and IGF plus HGF electrodes-inserted guinea pigs
were 603 ± 480/μm2 and 968 ± 466/μm2, 581 ± 483/μm2,
520 ± 386/μm2, and 649 ± 628/μm2 (mean ± SD), respect-
ively. No significant differences in the SGC densities were
found, but SGNs were most preserved in hydrogel-coated
electrode inserted guinea pigs. In either non-coated, IGF1
or HGF guinea pigs, the SGC densities were relatively
lower when compared to those in hydrogel-coated elec-
trode group.Fibrous tissue response of implanted cochleae
Fibrous capsule stained with trichrome was observed
around the implants and the capsular thickness was
measured (Figures 3 and 4C). Out of 22 implanted coch-





Figure 3 Representative photomicrographs of the guinea pig specimens. Mid-modiolar cochlear sections from groups A (non-coated),
B (gelatin hydrogel coating), C (hydrogel + IGF1), D (hydrogel + HGF) and E (hydrogel + IGF1 + HGF). Third and basal turns of the cochlea are
shown. In some cases, dense fibrous tissue was observed around the inserted electrode arrays (asterisks). Mallory’s trichrome staining. Scale bar,
250 μm.
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tissue occupying the scala tympani in cross section (thick-
ness varying from 160.2 to 338.6 μm). These 9 GPs were
found in dummy (non-coated) electrode group or IGF1,
HGF, and IGF1 plus HGF groups, but not in the hydrogel-
only group. Although not statistically significant, a general
trend was found that hydrogel coating tended to suppress
fibrous tissue formation compared to bare silicone, which
showed biocompatibility of the coating. Growth factor-
administered groups showed denser fibrous tissue, but the
difference was not statistically significant.
Discussion
Our findings demonstrate that efficient transfer of neuro-
protective growth factors into the inner ear is achievablewith a hydrogel-coated CI electrode. Adsorption and re-
lease profile analyses in the present study confirmed the
sustained delivery of IGF1 to the cochlear fluid for at least
48 h by way of the biodegradable hydrogel. In addition,
in vivo ABR hearing record indicated that the local appli-
cation of growth factors to the inner ear is an effective
method for the protection of the cochlea from insertional
trauma. The functional and morphologic protection of the
HC and SGN was observed at 28 days after growth factor
application, indicating that its biological effects were suc-
cessfully maintained during this period. Moreover, no ad-
verse events including functional and histological reaction
were observed in treated animals.
Biodegradable hydrogel coating on CI electrodes is rela-










































































































Figure 4 Survival of the cochlear cells and fibrous tissue formation. (A) The survival rates (mean ± SD) of the inner (left column) and outer
(right column) hair cells in the second, third, and basal turns of operated guinea pigs from each experimental group. (B) The survival rates
(mean ± SD) of spiral ganglion cells in the Rosenthal’s canal. (C) Thickness of the fibrous formation (mean ± SD) of the basal turns from each group.
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ear injection. The inner ear is separated from the sys-
temic circulation by a blood-labyrinth barrier that
limits penetration of certain molecules from the sys-
temic circulation to the inner ear. Previous studies in-
vestigating the efficacy of neurotrophins against inner
ear degeneration have used the implantation of an os-
motic minipump [24] or gene transfer by virus vectors
[25,26] as drug-application methods. The osmotic mini-
pump requires extra surgery, which includes implant-
ation of the pump into the subcutaneous tissue.
Although recent gene transfer studies using virus vectors
have shown no significant toxicity, this risk remains a
major problem in clinical applications. In contrast with
virus vectors, biodegradable hydrogels are made from por-
cine collagen and have no toxicity [20,21]. We, therefore,
consider the biodegradable electrode coating to be better
suited for clinical use than the osmotic minipump or gene
transfer. Another study demonstrated that polypyrrole/
para-toluene sulfonate-containing neurotrophin-3 (Ppy/
pTS/NT3)-coated electrode arrays had lower electrically
evoked ABR thresholds and greater SGN densities in im-
planted cochleae [1].
Efforts to reduce degeneration in the inner ear have
identified several agents for the protection of HCs orSGNs. Among these are trophic growth factors, several of
which are commercially available for clinical use. Our
focus was on IGF1, which has been approved for clinical
application. In a preceding paper, we found that IGF1
could activate both the PI3K/Akt and MEK/ERK pathways
in the neomycin-injured mouse cochlea [18]. The PI3K/
Akt pathway maintained the number of IHCs through
the inhibition of apoptosis and the MEK/ERK pathway
was activated in the Hensen’s and Claudius’ cells and
induced the cell cycle promotion that partly contrib-
uted to the maintenance of the OHCs. We reported the
efficacy of topical IGF1 application for sudden sensori-
neural hearing loss (SSHL) that is resistant to systemic
glucocorticoid treatments in a single arm, non-randomized
and open trial [19].
Another promising agent is HGF, which was originally
identified as a protein which stimulates proliferation of
the hepatocytes. We found that local HGF treatment sig-
nificantly reduced ABR threshold shifts and loss of outer
hair cells in the basal portion of damaged cochleae due
to noise exposure [15]. HGF activates ectodermal cell
outgrowth in a similar pathway as IGF1 [27]; however,
since HGF has different molecular weight (69 kDa for α-
subunit and 34 kDa for β-subunit) compared to that of
IGF1 (7.6 kDa), HGF may abundantly distribute in the
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tribution of IGF1. Therefore, we speculated that a com-
bined approach (IGF1 and HGF) may be beneficial to
protect wider portion of the cochlea.
In this study, hydrogel coating alone protected the
cochlea from insertional trauma, especially in the lower
tone (Figure 2). Hydrogel coating also increased SGC
and IHC survival in upper turns of the cochlea, but the
differences were not statistically significant. Roland et al.
suggested that insertional trauma arises partially from a
perilymph fluid leak from cochleostomy [28]. Hydrogels
are commonly known as superabsorbents because they
can absorb 400 to 1500 times their dry weight in water.
Therefore, an interesting possibility arises that hydrogel
coating worked as a natural sealant around the insertion
site, thus preventing perilymph leakage. However, the
protective effect of hydrogel coating was reduced after
4 weeks following surgery.
In contrast, the effect of the growth factors was in-
creased over time. This was most evident in higher tones
(16 kHz). OHC survival was most promoted in the basal
turns, but the differences were not statistically signifi-
cant. According to the release profile data (Figure 1B),
growth factor release from the electrode rapidly declined
even if combined with gelatin hydrogels. Sustained pro-
proliferative effect of growth factors in our study might
have resulted from the natural sealant effect of hydrogel
coating. Nevertheless, fibrous tissue formation was ac-
celerated in the presence of growth factors (IGF1, HGF
or IGF plus HGF). Because of the limitation in sample
numbers, these results should be fully confirmed with
further experiments in the near future.Conclusions
Growth factor-eluting gelatin hydrogel coatings for CI
electrodes have been described. This coating successfully
released growth factors in collagenase-added physio-
logical saline and when implanted into guinea pig coch-
leae, coated electrodes promoted a significant recovery
of hearing compared to plain silicone electrodes, as indi-
cated from lower ABR thresholds. Given the absence of
adverse effect in the operated GPs, these electrodes ap-
pear promising for clinical use. With atraumatic inser-
tion techniques, they would seem to be well suited for
patients who have substantial residual hearing and who
would benefit from combined electrical and acoustic
stimulation.
Abbreviations
IGF1: Insulin-like growth factor 1; HGF: Hepatocyte growth factor; CI: Cochlar
implant; SGN: Spiral ganglion neuron; PI3K: Phosphoinositide-3-kinase;
Akt: Protein kinase B; MEK: Mitogen-activated protein kinase/extracellular
signal-regulated kinase kinase; ERK: Extracellular signal-regulated kinase;
ABR: Auditory-evoked brainstem response; HC: Auditory hair cells; IHC: Inner
hair cells; OHC: Outer hair cells; SSHL: Sudden sensorineural hearing loss.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
YSK, TN and JI designed and conducted the research and wrote the
manuscript; YT, HT and AI provided the material; YSK, LY and TN analyzed
the data. TN had primary responsibility for the final content. All authors read
and approved the final manuscript.Acknowledgements
The authors would like to thank Dr. Yu Kimura (Tabata lab) for providing
technical advice and hydrogels, Dr. Norio Yamamoto (Kyoto University) and
Dr. Makoto Kinoshita (University of Tokyo) for critical reviews. We are also
grateful to all Kyoto University ear lab members for technical assistance and
critical review of the manuscript.
This study was supported by a Grant-in-Aid for Scientific Research (S)(23229009)
to JI from the Ministry of Education, Science, Sports, Culture and Technology in
Japan, in part by a Grant-in-Aid for Research on Sensory and Communicative
Disorders (H21-Kankaku-ippan-006 to TN and H22-Kankaku-wakate-006 to YSK)
from the Japanese Ministry of Health, Labor and Welfare, and by a research
resident fellowship to YSK from the Japan Foundation for Aging and Health.
Author details
1Department of Otolaryngology-Head and Neck Surgery, Graduate School of
Medicine, University of Tokyo, Tokyo, Japan. 2Department of Otolaryngology-Head
and Neck Surgery, Graduate School of Medicine, Kyoto University, Kawaharacho
54, Shogoin, Sakyo-ku, 606-8507 Kyoto, Japan. 3Department of Biomaterials, Field
of Tissue Engineering, Institute for Frontier Medical Science, Kyoto University,
Kyoto, Japan. 4Department of Digestive and Life-style Related Diseases, Graduate
School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
5Department of Otolaryngology and Head and Neck Surgery, Xijing Hospital, Xi’an,
China.
Received: 30 April 2014 Accepted: 24 September 2014
References
1. Richardson RT, Wise AK, Thompson BC, Flynn BO, Atkinson PJ, Fretwell NJ,
Fallon JB, Wallace GG, Shepherd RK, Clark GM, O'Leary SJ: Polypyrrole-
coated electrodes for the delivery of charge and neurotrophins to
cochlear neurons. Biomaterials 2009, 30:2614–2624.
2. Choi CH, Oghalai JS: Predicting the effect of post-implant cochlear
fibrosis on residual hearing. Hear Res 2005, 205:193–200.
3. Huang CQ, Tykocinski M, Stathopoulos D, Cowan R: Effects of steroids and
lubricants on electrical impedance and tissue response following
cochlear implantation. Cochlear Implants Int 2007, 8:123–147.
4. Jia H, Venail F, Piron JP, Batrel C, Pelliccia P, Artieres F, Uziel A, Mondain M:
Effect of surgical technique on electrode impedance after cochlear
implantation. Ann Otol Rhinol Laryngol 2011, 120:529–534.
5. Chang A, Eastwood H, Sly D, James D, Richardson R, O'Leary S: Factors
influencing the efficacy of round window dexamethasone protection of
residual hearing post-cochlear implant surgery. Hear Res 2009, 255:67–72.
6. Bas E, Dinh CT, Garnham C, Polak M, Van de Water TR: Conservation of
hearing and protection of hair cells in cochlear implant patients’ with
residual hearing. Anat Rec (Hoboken) 2012, 295:1909–1927.
7. Gantz BJ, Turner C, Gfeller KE, Lowder MW: Preservation of hearing in
cochlear implant surgery: advantages of combined electrical and
acoustical speech processing. Laryngoscope 2005, 115:796–802.
8. Gstoettner WK, van de Heyning P, O'Connor AF, Morera C, Sainz M,
Vermeire K, McDonald S, Cavalle L, Helbig S, Valdecasas JG, Anderson I,
Adunka OF: Electric acoustic stimulation of the auditory system: results
of a multi-centre investigation. Acta Otolaryngol 2008, 128:968–975.
9. Eshraghi AA, Adil E, He J, Graves R, Balkany TJ, Van De Water TR: Local
dexamethasone therapy conserves hearing in an animal model of
electrode insertion trauma-induced hearing loss. Otol Neurotol 2007,
28:842–849.
10. James DP, Eastwood H, Richardson RT, O'Leary SJ: Effects of round window
dexamethasone on residual hearing in a Guinea pig model of cochlear
implantation. Audiol Neurootol 2008, 13:86–96.
Kikkawa et al. Journal of Translational Medicine 2014, 12:280 Page 9 of 9
http://www.translational-medicine.com/content/12/1/28011. Meyer H, Stover T, Fouchet F, Bastiat G, Saulnier P, Baumer W, Lenarz T,
Scheper V: Lipidic nanocapsule drug delivery: neuronal protection for
cochlear implant optimization. Int J Nanomedicine 2012, 7:2449–2464.
12. Tabata Y, Yamada K, Miyamoto S, Nagata I, Kikuchi H, Aoyama I, Tamura M,
Ikada Y: Bone regeneration by basic fibroblast growth factor complexed
with biodegradable hydrogels. Biomaterials 1998, 19:807–815.
13. Ozeki M, Tabata Y: Affinity evaluation of gelatin for hepatocyte growth
factor of different types to design the release carrier. J Biomater Sci Polym
Ed 2006, 17:139–150.
14. Lee KY, Nakagawa T, Okano T, Hori R, Ono K, Tabata Y, Lee SH, Ito J: Novel
therapy for hearing loss: delivery of insulin-like growth factor 1 to the
cochlea using gelatin hydrogel. Otol Neurotol 2007, 28:976–981.
15. Inaoka T, Nakagawa T, Kikkawa YS, Tabata Y, Ono K, Yoshida M, Tsubouchi
H, Ido A, Ito J: Local application of hepatocyte growth factor using
gelatin hydrogels attenuates noise-induced hearing loss in guinea pigs.
Acta Otolaryngol 2009, 129:453–457.
16. Kikkawa YS, Nakagawa T, Tsubouchi H, Ido A, Inaoka T, Ono K, Ito J:
Hepatocyte growth factor protects auditory hair cells from
aminoglycosides. Laryngoscope 2009, 1:2027–2031.
17. Fujiwara T, Hato N, Nakagawa T, Tabata Y, Yoshida T, Komobuchi H, Takeda
S, Hyodo J, Hakuba N, Gyo K: Insulin-like growth factor 1 treatment via
hydrogels rescues cochlear hair cells from ischemic injury. Neuroreport
2008, 19:1585–1588.
18. Hayashi Y, Yamamoto N, Nakagawa T, Ito J: Insulin-like growth factor 1
inhibits hair cell apoptosis and promotes the cell cycle of supporting
cells by activating different downstream cascades after pharmacological
hair cell injury in neonatal mice. Mol Cell Neurosci 2013, 56:29–38.
19. Nakagawa T, Sakamoto T, Hiraumi H, Kikkawa YS, Yamamoto N, Hamaguchi
K, Ono K, Yamamoto M, Tabata Y, Teramukai S, Tanaka S, Tada H, Onodera
R, Yonezawa A, Inui K, Ito J: Topical insulin-like growth factor 1 treatment
using gelatin hydrogels for glucocorticoid-resistant sudden sensorineural
hearing loss: a prospective clinical trial. BMC Med 2010, 8:76.
20. Tabata Y, Miyao M, Ozeki M, Ikada Y: Controlled release of vascular
endothelial growth factor by use of collagen hydrogels. J Biomater Sci
Polym Ed 2000, 11:915–930.
21. Young S, Wong M, Tabata Y, Mikos AG: Gelatin as a delivery vehicle for
the controlled release of bioactive molecules. J Control Release 2005,
109:256–274.
22. Kinoshita M, Sakamoto T, Kashio A, Shimizu T, Yamasoba T: Age-related
hearing loss in Mn-SOD heterozygous knockout mice. Oxid Med Cell
Longev 2013, 2013:325702.
23. Ogita H, Nakagawa T, Lee KY, Inaoka T, Okano T, Kikkawa YS, Sakamoto T,
Ito J: Surgical invasiveness of cell transplantation into the guinea pig
cochlear modiolus. ORL J Otorhinolaryngol Relat Spec 2009, 71:32–39.
24. Sly DJ, Hampson AJ, Minter RL, Heffer LF, Li J, Millard RE, Winata L, Niasari A,
O'Leary SJ: Brain-derived neurotrophic factor modulates auditory
function in the hearing cochlea. J Assoc Res Otolaryngol 2012, 13:1–16.
25. Wang H, Murphy R, Taaffe D, Yin S, Xia L, Hauswirth WW, Bance M,
Robertson GS, Wang J: Efficient cochlear gene transfection in guinea-pigs
with adeno-associated viral vectors by partial digestion of round window
membrane. Gene Ther 2012, 19:255–263.
26. Iizuka T, Kanzaki S, Mochizuki H, Inoshita A, Narui Y, Furukawa M, Kusunoki T,
Saji M, Ogawa K, Ikeda K: Noninvasive in vivo delivery of transgene via
adeno-associated virus into supporting cells of the neonatal mouse
cochlea. Hum Gene Ther 2008, 19:384–390.
27. Boccaccio C, Ando M, Tamagnone L, Bardelli A, Michieli P, Battistini C,
Comoglio PM: Induction of epithelial tubules by growth factor HGF
depends on the STAT pathway. Nature 1998, 391:285–288.
28. Roland JT, Huang TC, Fishman AJ: Cochlear Implant Electrode/History,
Choices, and Insertion Techniques. In Cochlear Implants. Edited by
Waltzman SB, Roland JT. New York: Thieme Medical Publishers; 2006:124.
doi:10.1186/s12967-014-0280-4
Cite this article as: Kikkawa et al.: Growth factor-eluting cochlear implant
electrode: impact on residual auditory function, insertional trauma, and
fibrosis. Journal of Translational Medicine 2014 12:280.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
